Status:
TERMINATED
Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Conditions:
Advanced Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clin...
Eligibility Criteria
Inclusion
- Histologically confirmed colorectal adenocarcinoma
- Received prior therapy, at least two regimens, containing a fluoropyrimidine, oxaliplatin, and irinotecan
- Have at least one measurable tumor, as defined by RECIST
- Must be capable of maintaining a central venous line access
Exclusion
- Had previous anti-tumor therapy in the 3 weeks prior to study entry
- Have not recovered from all toxicities (excluding alopecia) from prior therapy to baseline or ≤grade 1 prior to study entry
- Have another malignancy in the past 3 years except curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00824161
Start Date
January 1 2009
End Date
December 1 2010
Last Update
April 23 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Cancer Institute
East 34th Street, New York, New York, United States, NY 10016
2
The University of Texas M.D. Anderson Cancer Center
Holcombe Boulevard, Houston, Texas, United States, TX 77030
3
The Center for Cancer and Blood Disorders
West Magnolia Avenue, Fort Worth, Texas, United States, TX 76104